Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm

Circulation Journal

Volumn 72, Issue 5, 2008, Pages 709-715

  Imai, Shinobu ^a   Saito, Fumio ^a   Takase, Hidehito ^a   Enomoto, Mitsunobu ^a   Aoyama, Hiroshi ^a   Yamaji, Satoshi ^a   Yokoyama, Katsuaki ^a   Yagi, Hiroshi ^a   Kushiro, Toshio ^a   Hirayama, Atsushi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bepridil; Class Ic antiarrhythmic drug; Persistent atrial fibrillation; Pharmacological cardioversion

Indexed keywords

AMIODARONE; APRINDINE; ATRIAL NATRIURETIC FACTOR; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CIBENZOLINE; DIGITALIS; FLECAINIDE; PILSICAINIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEART ARREST; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MONOTHERAPY; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; QRS COMPLEX; QT INTERVAL; SINUS BRADYCARDIA; SINUS RHYTHM; TORSADE DES POINTES;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL NATRIURETIC FACTOR; BEPRIDIL; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FLECAINIDE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; LIDOCAINE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; SINOATRIAL NODE; TREATMENT OUTCOME;

EID: 44149112534     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.709     Document Type: Article

References (21)

1. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385-2390.
2. Prystowsky EN, Freeland S, Branyas NA, Rardon DP, Fogel RI, Padanilam BJ, et al. Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14(Suppl): S287-S290.
3. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, Chlouverakis GI, Vardas PE. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1999; 33: 966-971.
4. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-475.
5. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
6. Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S, et al. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 2007; 71: 1250-1257.
7. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-525.
8. + channels in rat atrium: Electrical remodeling in paroxysmal atrial tachycardia. Circulation 2000; 101: 2007-2014.
9. 2+ channel by bepridil. Pharmacology 2005; 74: 174-181.
10. Nishida K, Fujiki A, Sakamoto T, Iwamoto J, Mizumaki K, Hashimoto N, et al. Bepridil reverses atrial electrical remodeling and L-type calcium channel downregulation in a canine model of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18: 765-772.
11. Kobayashi S, Reien Y, Ogura T, Saito T, Masuda Y, Nakaya H. Inhibitory effect of bepridil on hKv1.5 channel current: Comparison with amiodarone and E-4031. Eur J Pharmacol 2001; 430: 149-157.
12. Fujiki A, Sakamoto T, Iwamoto J, Nishida K, Nagasawa H, Mizumaki K, et al. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. Circ J 2006; 70: 1138-1141.
13. Roy D, Paillard F, Cassidy D, Bourassa MG, Gutkowska J, Genest J, et al. Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol 1987; 9: 509-514.
14. van den Berg MP, Tjeerdsma G, Jan de Kam P, Boomsma F, Crijns HJ, van Veldhuisen DJ. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. Eur J Heart Fail 2002; 4: 255-262.
15. Wozakowska-Kaplon B, Opolski G, Kosior D, Janion M. An increase in plasma atrial natriuretic peptide concentration during exercise predicts a successful cardioversion and maintenance of sinus rhythm in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol 2000; 23: 1876-1879.
16. Yoshihara F, Nishikimi T, Sasako Y, Hino J, Kobayashi J, Minatoya K, et al. Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: Plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure. J Am Coll Cardiol 2002; 39: 288-294.
17. Wozakowska-Kaplon B, Opolski G. Concomitant recovery of atrial mechanical and endocrine function after cardioversion in patients with persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1716-1720.
18. Wozakowska-Kaplon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol 2004; 93: 1555-1558.
19. Prystowsky EN. Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 1992; 69: 63D-67D.
20. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666.
21. Perelman MS, McKenna WJ, Rowland E, Krikler DM. A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. Br Heart J 1987; 46: 339-344.